Divi's Labs: Strong FY25 Results Clouded by Tax Disputes

Introduction

Divi's Laboratories Limited, a leading pharmaceutical company, has presented a mixed picture to its investors. While the company announced strong financial results for the fiscal year ending March 31, 2025, and a substantial dividend, it is also navigating significant challenges on the taxation front, including a large GST demand and ongoing income tax appeals. This combination of robust operational performance and regulatory hurdles creates a complex outlook for the Hyderabad-based firm.

Stellar Annual Financial Performance

The company's standalone financial results for the fiscal year showcased significant growth. Revenue from operations surged by 20% to reach ₹9,198 crores, a notable increase from the ₹7,665 crores recorded in the previous financial year. This top-line growth translated effectively to the bottom line. Profit before tax (PBT) for the year stood at ₹2,929 crores, up from ₹2,132 crores in the prior year. Consequently, profit after tax (PAT) grew to ₹2,209 crores compared to ₹1,576 crores previously. The company also noted that it has opted for the tax regime under Section 115BAA of the Income Tax Act, 1961, starting this financial year.

Consolidated Figures Reflect Growth

The Group's consolidated performance was also strong. Total consolidated income for the year was ₹9,712 crores, compared to ₹8,184 crores in the previous year. Consolidated profit before tax rose to ₹2,916 crores from ₹2,163 crores, while the consolidated profit after tax for the year was ₹2,191 crores, up from ₹1,600 crores in the prior year. These figures indicate that the company's core operations remain healthy and are on a growth trajectory.

Shareholder Rewards and Future Investments

In a move reflecting confidence in its financial position, the Board of Directors has recommended a dividend of ₹30 per equity share of face value ₹2 each, which translates to a 1,500% dividend. The total dividend payout amounts to ₹796 crores, representing 36% of the standalone profit after tax. The record date for determining eligible members for the dividend is set for July 25, 2025, subject to shareholder approval at the upcoming Annual General Meeting (AGM). Furthermore, the company continues to invest in its future, with capital works in progress across all locations amounting to ₹1,022 crores as of March 31, 2025.

The Shadow of Tax Disputes

Despite the positive financial news, Divi's Labs is contending with significant tax-related issues. The company received a demand notice from the GST department for ₹164 crore. This notice, issued by the Ranga Reddy GST Commissionerate, includes an Integrated GST (IGST) demand of ₹82.04 crore and an equivalent penalty of ₹82.04 crore. This development adds a layer of financial uncertainty.

Ongoing Income Tax Appeals

In addition to the GST notice, the company is also engaged in a dispute with the Income Tax department. The Assessing Officer (AO) had proposed additions of ₹15.55 crore for the Assessment Year (AY) 2020-21 and ₹7.97 crore for AY 2021-22. After the Dispute Resolution Panel (DRP) dismissed the company's objections, the AO passed final assessment orders confirming these additions. The Revenue department has now appealed a subsequent order to the Income Tax Appellate Tribunal (ITAT), indicating the matter is yet to be fully resolved.

Recent Quarterly Performance

A look at the company's recent quarterly performance for the July-September period provides additional context. While revenue for the quarter was ₹1,909 crore, meeting market expectations, the net profit declined by 29.5% year-on-year to ₹348 crore. The operating profit (EBITDA) also fell by 22.9% to ₹479 crore, with the EBITDA margin contracting significantly to 25.1% from 33.5% in the same period last year. This suggests that while the full-year results were strong, the company has faced margin pressures more recently.

Analysis and Market Outlook

Investors are now weighing the company's strong annual growth and generous dividend against the backdrop of significant tax liabilities and a weaker recent quarter. The ₹164 crore GST demand and the ongoing ITAT case represent potential financial outflows that could impact liquidity. While the company's operational strength and continued capital investments are positive indicators, the resolution of these tax disputes will be a key factor for the stock's performance. The management's ability to navigate these regulatory challenges while sustaining its growth momentum will be closely watched by the market.

Conclusion

Divi's Laboratories has delivered a robust performance for the fiscal year, rewarding shareholders and investing in future capacity. However, the company's path is not without obstacles. The pending tax disputes amounting to a considerable sum cast a shadow over the otherwise bright financial results. The market will await further clarity on these matters, particularly the outcomes of the GST demand and the income tax appeals, to fully assess the company's future financial health.